Search results for "CIRRHOSIS"

showing 10 items of 964 documents

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods

2020

Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver b…

AdultMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaArticle SubjectPopulationBariatric SurgeryPrevalence NAFLD Fibrosis Bariatric Surgery Non invasive diagnosis UltrasoundGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicinePrevalenceHumansObesityeducationNonalcoholic steatohepatitis (NASH)Retrospective StudiesUltrasonographyeducation.field_of_studyGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryFatty liverRRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseFibrosisSurgeryObesity Morbidultrasound (US)ROC Curve030220 oncology & carcinogenesisLiver biopsyMedicine030211 gastroenterology & hepatologyFemalebusinessResearch ArticleNonalcoholic fatty liver disease (NAFLD)BioMed Research International
researchProduct

Intraoperative assessment of liver organ condition by the procurement surgeon.

2007

Abstract Generally the transplanting surgeon accepts or declines the offer of a marginal organ in view of all available information. Hence, in some cases it is the procurement surgeon who decides about the suitability for potential further liver transplantation. Methods From January 1, 2003 to September 30, 2005, a total of 402 organ procurement operations were performed in our region. Results Due to infrastructural problems in nine cases intraoperative evaluation of liver biopsies was not achievable in time, and the decision to reject the organs was based on the procurement surgeon’s clinical assessment. The main reason for liver rejection was alleged extreme steatosis, (6 of 9) or liver c…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationProcurementMonitoring IntraoperativeMedicineHepatectomyHumansOrgan donationDonor poolAgedTransplantationbusiness.industryMiddle Agedmedicine.diseaseSurgeryTransplantationOrgan procurementLiverTissue and Organ HarvestingSurgeryFemalebusinessClinical evaluationTransplantation proceedings
researchProduct

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

Current practice of chronic hepatitis B treatment in Southern Italy

2012

Abstract Background Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. Methods A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Results Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (…

AdultMalemedicine.medical_specialtyHBsAgGuanineCirrhosisOrganophosphonatesPyrimidinonesNucleosides analoguesAntiviral AgentsPolyethylene GlycolsYoung AdultHepatitis B ChronicChronic hepatitisInterferonPegylated interferonInternal medicineHBVInternal MedicinemedicineHumansHepatitis B e AntigensPractice Patterns Physicians'TenofovirProspective cohort studyAgedAged 80 and overTelbivudinebusiness.industryAdenineAge FactorsInterferon-alphaNucleosidesMiddle AgedHBV; Interferon; Nucleosides analogues; Nucleotides analoguesNucleotides analoguesmedicine.diseaseRecombinant ProteinsItalyLamivudineCurrent practiceImmunologyInterferonFemalePreviously treatedbusinessThymidinemedicine.drugEuropean Journal of Internal Medicine
researchProduct

Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis.

2008

In post-infancy, multinucleated giant cell hepatitis is rare. Various conditions and diseases associated with post-infantile giant cell hepatitis have been described, but the pathogenesis remains unknown. In this paper we review the case reports of four patients (3 male, 1 female; aged 22 to 32 years) with primary sclerosing cholangitis and autoimmune hepatitis. The follow-up ranges from five to seven years. All patients showed cholestasis and repeated elevation of hepatic transaminases. Patients with viral infections, metabolic disorders and toxic influences were excluded. Histopathology of liver tissue in all four patients revealed giant cell formation with up to 20 nuclei in 20-70% of al…

AdultMalemedicine.medical_specialtyPathologyCirrhosisCholangitisAutoimmunityAutoimmune hepatitisGiant CellsPrimary sclerosing cholangitisHepatitisCholestasisAdrenal Cortex HormonesHLA AntigensmedicineHumansAspartate AminotransferasesAutoimmune diseaseHepatitisCholangiopancreatography Endoscopic RetrogradeCholestasisHepatologybusiness.industryHistocytochemistryUrsodeoxycholic AcidAlanine TransaminaseBilirubinmedicine.diseaseSerologyGiant cellHistopathologyFemalebusinessImmunosuppressive AgentsLiver
researchProduct

Anti-actin antibodies in celiac disease: correlation with intestinal mucosa damage and comparison of ELISA with the immunofluorescence assay.

2005

The presence in the sera of celiac disease (CD) patients of anti-actin autoantibodies (AAAs) has been suggested as a marker of severe intestinal villus atrophy (1). AAAs have been detected with an immunofluorescence (IF) technique and seem to contribute to villus cytoskeleton damage and to the pathogenesis of intestinal damage in CD (2). The aims of the present study were to evaluate the relationship between the presence of serum IgA AAAs and severity of intestinal mucosa damage in CD patients and to compare the IF assay with a new ELISA for IgA AAA determination. We enrolled 150 individuals in the study. IgA AAAs were assayed in 58 consecutive CD patients diagnosed between January and Dece…

AdultMalemedicine.medical_specialtyPathologySettore MED/09 - Medicina InternaAdolescentClinical Biochemistryanti-actin autoantibodieFluorescent Antibody TechniqueEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisGastroenterologyCoeliac diseasePrimary biliary cirrhosisIntestinal mucosaInternal medicinemedicineHumansIntestinal MucosaChildPediatric gastroenterologyAutoantibodiesbusiness.industryBiochemistry (medical)Intestinal villusAutoantibodyInfantMiddle Agedmedicine.diseaseActinsImmunoglobulin AFood intoleranceanti-actin autoantibodies; celiac disease; ELISAmedicine.anatomical_structureChild PreschoolFemaleELISAbusinessceliac disease
researchProduct

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

2004

Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results: A total of 286 sustained virological responders and 50 b…

AdultMalemedicine.medical_specialtyPlus ribavirinCirrhosisHepatocellular-CarcinomaAdolescentFibrosiPopulationAlpha interferonAntiviral AgentsSDG 3 - Good Health and Well-beingInternal medicinemedicineHumansDecompensationeducationSurvival analysisAgededucation.field_of_studyCirrhosibusiness.industryIncidence (epidemiology)Follow-upNatural-historyGastroenterologyCohortHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurvival AnalysisImpactTreatment OutcomeLiverHepatocellular carcinomaImmunologyRegression AnalysisFemaleTherapyInterferonsbusinessAlpha-interferonGut
researchProduct

Long-term course of interferon-treated chronic hepatitis C

1998

Abstract Background/Aims: To evaluate whether sustained response to α-interferon improves clinical outcome in patients with chronic hepatitis C. Methods: A cohort of 410 consecutive patients (65% with chronic hepatitis, 35% with cirrhosis) were treated with α-interferon in two trials (mean follow-up 62.1 months, range 7–109 months). All were serum HCV RNA positive before therapy and received first 10 then 5 million units of α-2b or α-n1 interferon three times weekly for 6 to 12 months. Sustained response was defined as normal aminotransferases 12 months after stopping interferon. Results: Sixty-two patients (15.1%: 54 with chronic hepatitis, eight with cirrhosis) were sustained responders. …

AdultMalemedicine.medical_specialtyTime FactorsCirrhosisHepacivirusHepatitis C virusStatistics as TopicAlpha interferonmedicine.disease_causeAntiviral AgentsGastroenterologyLiver diseaseInternal medicineAscitesmedicineHumansInterferon alfaHepatologybiologybusiness.industryInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseTreatment OutcomeImmunologyFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years

2004

Background & aims: Increased morbidity and mortality from liver disease have been reported in chronic hepatitis B surface antigen (HBsAg) carriers, but data on survival are equivocal. To assess the impact of hepatitis B virus (HBV) infection on survival and liver-related complications, we re-evaluated, after a mean follow-up of 30 years, a cohort of 296 blood donors excluded from donation 30 years ago when HBsAg screening became mandatory. Methods: Clinical and ultrasound examination and biochemical and virologic tests were performed. The cause of death was recorded and survival was compared with a control population of 157 HBV-negative blood donors selected at baseline. Results: Thirty-two…

AdultMalevirus DNAmedicine.medical_specialtyHBsAgHepatitis B virusCirrhosisBlood Donorsmedicine.disease_causeGastroenterologyserum HBVCohort StudiesLiver diseaseHepatitis B ChronicInternal medicinemedicineHumansProspective StudiesSurvival analysisCause of deathAgedHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryalcoholGastroenterologyHepatitis BMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseaseshepatitis B surface antigenItalygamma glutamyltransferaseHepatocellular carcinomaImmunologyCarrier StateFemalebusinessFollow-Up Studies
researchProduct